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Abstract
High-throughput drug screening has facilitated the discovery of drug combinations in can-
cer. Many existing studies adopted a full matrix design, aiming for the characterization of
drug pair effects for cancer cells. However, the full matrix design may be suboptimal as it
requires a drug pair to be combined at multiple concentrations in a full factorial manner. Fur-
thermore, many of the computational tools assess only the synergy but not the sensitivity of
drug combinations, which might lead to false positive discoveries. We proposed a novel
cross design to enable a more cost-effective and simultaneous testing of drug combination
sensitivity and synergy. We developed a drug combination sensitivity score (CSS) to deter-
mine the sensitivity of a drug pair, and showed that the CSS is highly reproducible between
the replicates and thus supported its usage as a robust metric. We further showed that CSS
can be predicted using machine learning approaches which determined the top pharmaco-
features to cluster cancer cell lines based on their drug combination sensitivity profiles. To
assess the degree of drug interactions using the cross design, we developed an S synergy
score based on the difference between the drug combination and the single drug dose-
response curves. We showed that the S score is able to detect true synergistic and antago-
nistic drug combinations at an accuracy level comparable to that using the full matrix design.
Taken together, we showed that the cross design coupled with the CSS sensitivity and S
synergy scoring methods may provide a robust and accurate characterization of both drug
combination sensitivity and synergy levels, with minimal experimental materials required.
Our experimental-computational approach could be utilized as an efficient pipeline for
improving the discovery rate in high-throughput drug combination screening, particularly for
primary patient samples which are difficult to obtain.
Author summary
Cancer is one of the main causes of death worldwide. Although new treatment strategies
have been achieved, they still have limited efficacy as cancer cells can easily develop drug
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resistance. To achieve more sustainable therapies to treat cancer, we need multi-targeted
drug combinations that can inhibit cancer cells more effectively and synergistically. How-
ever, the increasing number of possible drug combinations makes a full matrix design
unfeasible, even with automated drug screening instruments. Therefore, we proposed a
novel cross design to access drug combinations more efficiently. We further developed a
drug combination sensitivity score (CSS) that is tailored for the cross design to quantify
the efficacy of a drug combination. Using public datasets, we showed that the CSS is a
robust metric and highly predictive with an accuracy comparable to the experimental rep-
licates. We also developed a CSS-based synergy score to assess the degree of drug interac-
tion and showed its capability to correctly identify synergistic and antagonistic drug
combinations. Taken together, we showed that the cross design and its scoring methods
allow a more systematic and cost-effective evaluation of drug combinations. The proposed
experimental and computational techniques are expected to be widely applicable in the
field of drug combination discovery.
This is a PLoS Computational Biology Methods paper.
Introduction
Despite great advances in the understanding of cancer, there remains a major challenge to
develop more effective anti-cancer treatments. Next generation sequencing has revealed the
intrinsic heterogeneity in cancer genomes, which partly explains why patients respond differ-
ently to the same therapy [1]. To reach durable clinical responses, cancer patients who relapse
and become refractory to standard chemotherapy need novel multi-targeted drug combina-
tions which can effectively overcome the emergence of drug resistance [2–4]. Ideally, a poten-
tial drug combination should achieve therapeutic efficacy at reduced dosages, and therefore
minimize the toxicity and other side effects associated with high doses of single drugs [5–6].
Therefore, two important properties for a drug combination must be evaluated: sensitivity and
synergy. Sensitivity of a drug combination is defined as the level of treatment response, usually
measured in the unit of percentage inhibition of cell viability or growth. In contrast, synergy of
a drug combination is referred to the degree of drug interactions that contributes to the drug
combination sensitivity independent of the single drug effects [7].
In order to identify sensitive and synergistic drug combinations, high-throughput drug
screening has been applied on a large variety of cancer cell lines and more recently on patient-
derived cancer samples [8–9]. Many high-throughput drug combination screens test pairs of
drugs at a dose matrix, for which the cell viability or growth inhibition effects are measured
[10–11]. The dose-response matrix results from a full factorial design that involves multiple
dose combinations of a drug pair, and thus demands a relatively large amount of cancer cells.
For patient-derived cancer samples, which are challenging to obtain and restricted in volume,
the full matrix design may be infeasible to test even with a minimal number of drug combina-
tions. Furthermore, cancer samples of different genetic profiles are known to respond differ-
ently to the same treatment [12]. With the limited amount of drug combination data points, it
becomes a daunting task for any machine learning approach to navigate the combinatorial
space to pinpoint the most promising drug combinations that are selectively effective for indi-
vidual cancer samples [13].
Drug combination sensitivity score
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Furthermore, many existing computational tools for drug combination analysis focus on
the degree of interaction, i.e. drug synergy, but not the sensitivity of drug combinations. For
example, Combenefit [14] and SynergyFinder [15] have been developed to provide multiple
reference models to score drug synergy, such that drug combinations that produce higher
growth inhibition effects compared to the single drugs will be prioritized. There have been
multiple methods to score drug synergy [16], while the choice of the best synergy scoring
methods is under debate [7,17]. On the other hand, as synergy is a measure of drug interaction
while sensitivity is a measure of drug combination efficacy, these two metrics are expected to
capture distinct properties of a drug combination. Therefore, neglecting the drug combination
sensitivity may lead to a biased prioritization of drug combinations that are unable to kill can-
cer cells despite strong synergy [18]. However, unlike the sensitivity of single drugs which can
be directly derived from monotherapy dose-response curves [19], the sensitivity of a drug
combination remains largely undefined, as the same sensitivity can be achieved using different
dose combinations. Furthermore, there is a lack of scoring approaches to fully capture the syn-
ergy and sensitivity simultaneously, which should be ideally interpretable using the same scale,
e.g. percentage inhibitions [16].
To overcome these challenges, we proposed a cost-effective experimental and computational
procedure to facilitate the prioritization of drug combination synergy and sensitivity. We pro-
posed a novel experimental design to allow either drug to span over multiple doses while the
concentration of the other drug is fixed at its IC50 concentration. The resulting drug combina-
tion dose-response curves were utilized to determine a drug combination sensitivity score (CSS).
Using a large-scale drug combination study, referred to as the O’Neil data [20], we showed that
the CSS is highly reproducible, suggesting its robustness to be utilized as a metric for characteriz-
ing drug combination responses. Furthermore, we found that the CSS can be predicted at high
accuracy using chemical and pharmacological features of the drug combinations. To assess the
degree of synergy from the cross design, we developed an S synergy score based on the difference
between the observed CSS score and the baseline effect predicted by a reference model. As there
is no consensus on the reference model, we evaluated multiple variants of it and found that the S
score can detect the true synergistic and antagonistic drug combinations with high accuracy,
irrespective of which the reference model is used. Compared to the full matrix design, the cross
design requires minimal amount of experimental materials, while it still maintains a robust and
accurate characterization of both drug combination sensitivity and synergy levels. We foresee
that such a cross experimental design and its CSS and S scoring methods should allow a scale-up
of drug combination testing especially for patient-derived cancer cells. The R scripts for calculat-
ing and predicting CSS are available at https://github.com/amalyutina/CSS.
Materials and methods
The cross drug combination design
We proposed a cross design to test the synergy and sensitivity of a drug pair by first introduc-
ing the concepts of background drug and foreground drug: background drug is the drug fixed
at its IC50 concentration while foreground drug is added into the background drug with multi-
ple concentrations. We allow either drug in the pair to be the background drug, so that two
vectors of dose combinations will be intersected at the IC50 concentrations (Fig 1A). The dose-
response curves for these two vectors are usually measured in a unit of inhibition percentages
by cell viability or toxicity assays. Note that the cross design requires specifically the combina-
tions at the IC50 concentrations, which need to be determined based on the monotherapy
dose response curves. As shown in Fig 1B, as long as a minimal of two concentrations are
tested for a drug combination, the cross design will require less experimental materials than a
Drug combination sensitivity score
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full matrix design. For a combination screen that tests one concentration only, both the cross
design and the full matrix design converge to a point estimate of drug combination effects at
IC50. Therefore, we considered that the cross design is in general more cost-effective compared
to the full matrix design.
Determination of the CSS drug combination sensitivity scores
With the drug combination dose-response curves determined in the cross design, the CSS
summarizes the area under the curve similar to the scoring approaches [21–22]. Namely, a
four-parameter log-logistic function is used to fit the dose-response curve for a concentration
x of the foreground drug according to:
y ¼ ymin þ
ymax   ymin
1þ 10lðlog10IC50   log10xÞ
; ð1Þ
where ymin and ymax are the minimal and maximal percentage inhibition (the bottom and top
asymptotes of the curve, 0� y, ymin, ymax� 1); IC50 is the concentration of the foreground
drug with which the drug combination reaches 50% of ymax—ymin inhibition of the cell growth;
λ is the slope of the dose-response curve.
The dose-response curve (1) is transformed by substituting x with x' = log10(x) as:
y ¼ ymin þ
ymax   ymin
1þ 10lðlog10IC50  x
0
Þ
ð2Þ
The area under the log10-scaled dose-response curve (AUC) is determined according to
AUC ¼
ðc2
c1
ymin þ
ymax   ymin
1þ 10lðm  x
0
Þ
dx0 ¼ ymin c2   c1ð Þ þ ymax   yminð Þ
1
l
log10
1þ 10lðc2   mÞ
1þ 10lðc1   mÞ
� �
; ð3Þ
where [c1, c2] is the log10 concentration range for the foreground drug tested in the experi-
ment, and m = log10(IC50).
Fig 1. Drug combination cross design. (A) The cross design to determine the drug combination sensitivity score. Compared to the
full matrix design (left panel), only a single row and a single column from the matrix that correspond to the IC50 concentrations of
the two drugs are utilized for the calculation of CSS (middle panel). One drug is utilized as the background drug fixed at its IC50
concentration while the other drug becomes the foreground drug with multiple doses being titrated. The resulting two dose-response
curves will be summarized as the drug combination sensitivity score (CSS), from which the S synergy score can be determined as the
deviation from a reference model which predicts the expected percentage inhibition effect from monotherapy dose responses. (B)
Comparing the cross design with the full matrix design in terms of data size. Less materials are needed for the cross design when the
size of the full matrix is two or above.
https://doi.org/10.1371/journal.pcbi.1006752.g001
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The AUC is further normalized as the proportion of its maximal possible inhibition (i.e.
100% inhibition) according to:
AUC 0 ¼
AUC   inhminðc2   c1Þ
ð1   inhminÞðc2   c1Þ
; ð4Þ
where inhmin is the minimum inhibition level that is considered as the drug effect (by default it
is fixed at 10%, assuming that the inhibition below 10% is experimental noise, S1 Fig).
The CSS for the foreground drug is defined as a percentage which varies between 0 and
100:
CSS ¼ 100AUC 0 ð5Þ
As there are two drug combination dose-response curves depending on which drug is fixed
as the background drug, we refer to the results of Eq (5) for either scenario as CSS1 and CSS2.
The two variants of CSS are expected to reflect similarly the summarized % inhibition for a
given drug combination. We considered them as two samples that are generated from the
same random variable, and estimated the CSS as an average of CSS1 and CSS2, i.e.
CSS ¼
ðCSS1 þ CSS2Þ
2
ð6Þ
The O’Neil drug combination data
Dose-response was measured as percentage of cell viability and retrieved from the supplemen-
tary material of O’Neil et al. [20], which includes 22,737 drug combinations that involve 38
unique drugs in 39 cancer cell lines, representing 7 tissue types. At the first stage, single-drug
screening was done using 8 concentrations to determine the IC50 concentration for each drug
with six replicates. At the second stage, a 4 by 4 dose matrix was utilized to cover the span of
IC50 concentrations for a drug pair with four replicates. To utilize the cross design, we picked
up only the row and the column corresponding to the concentrations closest to the IC50 of the
single drugs. These two vectors thus allowed the fitting of drug combination dose-response
curves with which the CSS can be calculated. The cell viability percentage was first transformed
to inhibition percentage according to:
%inhibition ¼ 100   %viability ð7Þ
In our analysis, the CSS for a drug combination was determined based on the average %
inhibition of the four replicates. The robustness of the CSS scoring was assessed using the
Pearson correlation across the four replicates. All the correlation analyses utilized Pearson
correlations.
Predicting the CSS using machine learning approaches
With the CSS being determined for each drug combination, we sought to evaluate the predic-
tion accuracy of multiple machine learning methods. We considered a drug combination as a
combination of their targets and chemical fingerprints. We collected the known targets that
have been experimentally validated for the 38 drugs from Drugbank [23] and ChEMBL [24].
Furthermore, we also utilized the Similarity Ensemble Approach (SEA) to predict additional
secondary targets based on the chemical structures of the drugs [25]. The targets that were pre-
dicted with Z-score higher than 20, Tanimoto coefficient higher than 0.4 and P-value smaller
than 0.01 were included, following the previously reported filtering strategy [25]. The MACCS
Drug combination sensitivity score
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fingerprints of the drugs were determined using the SMILES strings with the R package rcdk
[26]. The resulting feature set for a single drug included 398 validated and predicted targets
and 166 MACCS fingerprints (S1 and S2 Tables). The feature vector for a drug combination
was determined as the bitwise OR operation over the features of its single drugs.
We compared three state-of-the-art machine learning methods for the CSS prediction: Elas-
tic Net [27], Random Forests [28] and Support Vector Machines [29]. Elastic Net is a regulari-
zation and feature selection method that combines both ridge and lasso regression by
including the L1 and L2 penalty terms, which are regulated by hyper parameters α and λ. The α
parameter controls the penalty term in the elastic net by giving more power either to the lasso
regression (when α is closer to 1) or to the ridge regression (when α is closer to 0). In our stud-
ies, α was selected from the interval [0.1, 1], which determines the level of compromise
between the lasso and ridge regressions. The λ parameter regulates the level of shrinkage and
was chosen to minimize the difference between predicted and actual CSS scores. Random For-
ests is an ensemble learning method that constructs multiple decision trees. In our studies, we
set the number of randomly selected predictors that is used at each split of the decision tree
equal to the rounded down square root of the number of variables. We utilized Support Vector
Machines with Radial Basis Function Kernel, which can be used not only for classification but
for regression problems. The tuning parameters are the cost parameter C that sets the penalty
for prediction error of a training point and a smoothing parameter σ, based on the loss func-
tion in cross-validation.
We focused on the model performance for predicting new drug combinations within the
same cell line, as the set of drug combinations in the training data did not overlap with that in
the test data. For each of the 39 cell lines, the number of drug combinations ranges from 290 to
688, with an average of 338. We randomly sampled 70% of the drug combinations to train
multiple machine learning models using 10-fold cross-validation, which splits the training
data randomly into 10 equally folds, 9 of which were used to fit the model and the remaining
one was used to evaluate the prediction accuracy. The model with the lowest RMSE out of the
10-fold cross validation was then used for predicting the CSS values for the remaining 30% of
the novel drug combinations as the testing data. As the sampling was done randomly for each
cell line, the training and the testing data were therefore balanced. Four metrics including coef-
ficient of determination (R2), root mean square error (RMSE), mean absolute error (MAE)
and Pearson correlation (COR) were utilized for evaluating the prediction performance on the
testing data. The whole procedure above was repeated 20 times for each cell line on the prede-
fined seeds, and the final model performance was obtained as the mean values of these itera-
tions. To benchmark the performance of the machine learning methods, we utilized one
randomly selected technical replicate as the best possible prediction to obtain the upper limit
of the performance. All the methods were implemented and evaluated using the R package
caret [30].
Determination of the S drug synergy scores
The advantage of CSS is that it allows a direct comparison of the sensitivity between a drug
combination and its single drugs, and hence facilitates the quantification of drug synergy. The
degree of synergy is often calculated as the deviation of the observed drug combination effect
from the reference, which is defined as the expectation effect if the drugs are not interacting.
However, how much the expected effect should be is a matter of mathematical modelling with
certain assumptions. As the choice of the ‘best’ synergy model is rather heuristic, we proposed
three variants of CSS-based synergy scores (termed as S scores) by assuming the reference
model as the sum, the maximal and the mean of the AUCs for the monotherapy drug
Drug combination sensitivity score
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responses:
Ssum ¼ CSS   sumðAUC1;AUC2Þ; ð8Þ
Smax ¼ CSS   maxðAUC1;AUC2Þ; ð9Þ
Smean ¼ CSS   meanðAUC1;AUC2Þ; ð10Þ
The AUC for a monotherapy drug response was defined according to [22]:
AUC ¼
a x   cþ log10ð1þ10
bðc  xÞÞ
b
� �
log10a
; ð11Þ
where [a, b, c] were the parameters to fit a logistic function on the single drug response at con-
centration x:
y ¼
a
1þ 10bðc  xÞ
ð12Þ
To evaluate the prediction accuracy of the S synergy scores, we defined a set of true syner-
gistic and antagonistic drug combinations as the gold standard, which were determined using
the full dose-response matrix data including the combination and monotherapy responses.
We utilized the R package synergyfinder [31] to calculate multiple versions of synergy scores
including the HSA (Highest Single Agency [32]), the Bliss [33], the Loewe [34] and the ZIP
synergy scores [35]. The principles of these four models are summarized below:
Consider that drug 1 at concentration x1 and drug 2 at concentration x2 were combined to
produce the inhibition effect of yc, while their respective single drug effects were y1(x1) and
y2(x2). The synergy score was calculated as the difference between yc and the expected effect ye
if there is no synergy. Each synergy scoring took a different model for ye:
1. HSA: ye is the maximal single drug effect, defining
SHSA ¼ yc   max ðy1ðx1Þ; y2ðx2ÞÞ ð13Þ
2. Bliss: ye is the expected effect of two drugs acting independently, defining
SBliss ¼ yc   ðy1ðx1Þ þ y2ðx2Þ   y1ðx1Þy2ðx2ÞÞ ð14Þ
3. Loewe: ye is the expected effect of a drug combined with itself, defining
SLoewe ¼ yc   y1ðx1 þ x2Þ ¼ yc   y2ðx1 þ x2Þ ð15Þ
4. ZIP: ye is the expected effect of two drugs that do not potentiate each other, defining
SZIP ¼ y
0
c   ðy
0
1
ðx1Þ þ y
0
2
ðx2Þ   y
0
1
ðx1Þy
0
2
ðx2ÞÞ; ð16Þ
where y0c; y
0
1
ðx1Þ and y
0
2
ðx2Þ are the fitted values based on the full-dose response matrix for
the combination and monotherapy drugs, respectively.
For each of the four models, the synergy scores were determined first for a given dose com-
bination and then were averaged over the full dose-response matrix. With the four synergy
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scores determined for each drug combination, the true synergistic and antagonistic drug com-
binations are those with all four synergy scores consistently higher than 5 and lower than 5,
respectively. The aim was then to use the S synergy score which was determined by the cross
design data to predict the ground truth determined by the full matrix design. The areas under
the ROC curve and the precision-recall curve were used for evaluating how well the S synergy
scores can predict the consensus drug combinations determined using the full dose-response
matrix data.
Results
CSS values are highly reproducible and robust
We applied the CSS scoring on the O’Neil drug combination data, which consists of 22,737
drug combinations for 39 cancer cells [20]. We found that the CSS1 and CSS2 values calculated
using either drug fixed at its IC50 concentration were highly correlated (Pearson correla-
tion = 0.82, p-value = 2×10−16; Fig 2A). Both CSS1 and CSS2 values ranged from 0 to 50, with a
marginal absolute difference of 5.62 (Fig 2B). As a CSS score can be directly interpreted as a
normalized average % inhibition of the drug combination response (Eqs 1–6), such a result
implies that about 5% inhibition difference is expected between CSS1 and CSS2. The high level
of consistency holds true for all the 39 cancer cell lines and the majority of the 38 unique
drugs, suggesting the robustness of the CSS scoring method (Fig 2C and 2D, S2 Fig). To evalu-
ate the robustness of the CSS values further, we permuted the O’Neil data randomly and recal-
culated the correlations between CSS1 and CSS2. The correlations deteriorated quickly to near
zero (Pearson correlation = 0.075, S3 Fig), suggesting that the high correlation can be attrib-
uted to the robustness of CSS on the actual drug combination data. We also found high corre-
lation between the CSS value and those derived from individual replicates (minimal Pearson
correlation = 0.97, S3 Table). In order to check whether the CSS values are within the range of
the CSS replicates for each drug combination, we calculated the minimal and maximal values
over the CSS replicates for each drug combination and plotted them together with CSS values
over the standard deviation of the CSS replicates. For a better visualization, we applied a gener-
alized additive model to smoothen the CSS lines and obtain 95% pointwise confidence interval
around the mean (S4 Fig). Only 4% of the drug combinations have the CSS values being out of
the CSS replicate-based limits, however this can be explained by the higher variance over the
replicates.
Notably, we found that drug combinations that involved bortezomib showed much lower
correlation (0.26) between the CSS1 and CSS2 values compared to other drug combinations.
Since the O’Neil data contains the replicates for single drug screening, we analyzed the coeffi-
cient of variation (CV) of the cell viability readout for each drug in the replicates. As expected,
we found that bortezomib has the highest CV (0.26), suggesting a relative low quality of the
drug combination sensitivity data involving this drug (S5 Fig). When filtering out the drug
combinations with a decreasing threshold of difference between CSS1 and CSS2, the remaining
drug combinations showed an increasing CSS1 and CSS2 correlation (S6 Fig). We found that
the threshold of 10 is close to the middle point that reached the correlation of 0.91 (i.e. the
average of 1 and 0.82). We therefore applied an empirical threshold of 10 to filter out the drug
combinations that were in poor quality, as CSS1 and CSS2 in these combinations showed big-
ger than 10% inhibition difference. In total, there were 18,905 drug combinations after the fil-
tering, constituting the 83.1% of the original data. As expected, the correlation between CSS1
and CSS2 was further improved (Pearson correlation = 0.93, p-value = 2×10−16). Furthermore,
the mean absolute difference between CSS1 and CSS2 was 3.83, which was comparable to the
variability determined from the technical replicates of CSS1 and CSS2 (2.92 and 3.06
Drug combination sensitivity score
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respectively), suggesting that the difference between CSS1 and CSS2 is similar to what is
expected when repeating the experiment. Taken together, CSS1 and CSS2 values are highly
consistent and therefore supported their averaging as a summary for the drug combination
sensitivity score.
CSS can be predicted using machine learning approaches
Given that the CSS is highly reproducible as a summary of the overall sensitivity of a drug com-
bination, we explored whether CSS can be predicted using pharmacological and chemical
information of the drugs. We considered a drug combination as a combination of its drugs’
target profiles as well as their chemical fingerprints, with which the machine learning
approaches illustrated in the previous section can be optimized by exploring the feature space
using the training data. We examined three major machine learning methods for predictions:
Elastic Net, Random Forests and Support Vector Machines.
We found that all of these machine learning approaches worked reasonably well, where
Elastic Net consistently achieved the best performance, with a mean MAE of 4.01 which is
comparable to that (2.07) of a technical replicate (Table 1). Note that in our cross-validation
setting the drug combinations in the test data were not present in the training data, however,
the machine learning methods were still able to predict the CSS values for new drug
Fig 2. Robustness and replicability of CSS. (A) The Pearson correlation of CSS1 and CSS2 over all the drug combinations colored
according to tissue type; (B) Density plot of the CSS1 and CSS2 distributions; (C) The Pearson correlation per cell line colored
according to tissue type; and (D) The Pearson correlation per drug colored according to drug target class.
https://doi.org/10.1371/journal.pcbi.1006752.g002
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combinations by exploring the feature similarity in the drug targets and chemical fingerprints.
The prediction performance thus validated our hypothesis that a drug combination can be
considered as a combination of their drug target profiles and chemical-structural properties,
with which the CSS score can be predicted with high confidence using state-of-the-art machine
learning approaches.
Since both the drug target profiles and chemical fingerprints were considered as the drug
combination features, we next evaluated their prediction performances separately using the
Elastic Net method. For drug-target profiles we collected known targets that were experimen-
tally validated as well as the additional secondary targets that were predicted with high confi-
dence using the SEA method. For chemical fingerprints we used the MACCS fingerprint
which contains 166 structural features [36]. As expected, when combining all the features the
model achieved the best performance (Table 2). We found that in general drug target profiles
were predictive of CSS, especially when including the experimentally validated targets. The
predicted targets using the SEA method did not improve the prediction accuracy significantly,
indicating that even though secondary drug target interactions may occur, most likely they
have minor functional impact that may not lead to changes in cancer cell viability and thus
does not contribute to the prediction of CSS. On the other hand, we found that chemical fin-
gerprints were less predictive of CSS compared to the drug-target profiles, suggesting that the
use of MACCS might be suboptimal to capture the relevant structural information for predict-
ing the drug combination sensitivity. However, as the focus of this study was to show the valid-
ity of using machine learning methods to predict the CSS score, we decided to explore other
chemical fingerprint features as a future step.
We considered the regression coefficients that were determined in the Elastic Net model as
an indication of their importance to contribute to the CSS prediction. We found that certain
drug target features were present with high coefficients across all the cell lines (Fig 3). For
Table 2. The prediction performances for drug-target features and chemical fingerprint features using Elastic
Net. RMSE: root mean square error, R2: coefficient of determination, COR: Pearson correlation, MAE: mean absolute
error.
Feature RMSE R2 COR MAE
Validated targets 5.66±1.27 0.77±0.07 0.88±0.04 4.26±0.95
Validated + predicted targets 5.70±1.22 0.76±0.06 0.87±0.04 4.34±0.95
Fingerprints 6.27±1.19 0.71±0.06 0.85±0.04 4.87±0.94
Validated targets + fingerprints 5.30±1.14 0.79±0.06 0.89±0.03 4.07±0.88
All features 5.20±1.11 0.80±0.06 0.90±0.03 4.01±0.86
All the values are mean+/-standard deviation.
https://doi.org/10.1371/journal.pcbi.1006752.t002
Table 1. The prediction performance for Elastic Net, Random Forests and Support Vector Machines, as compared
to the upper limit when randomly selecting one technical replicate as the prediction. RMSE: root mean square
error, R2: coefficient of determination, COR: Pearson correlation, MAE: mean absolute error.
Method RMSE R2 COR MAE
Elastic Net 5.20±1.11 0.80±0.06 0.90±0.03 4.01±0.86
Random Forests 6.30±1.18 0.71±0.07 0.85±0.04 4.75±0.9
Support Vector Machines 7.47±1.32 0.57±0.08 0.80±0.04 5.80±1.07
Technical replicate 2.87±0.59 0.93±0.04 0.97±0.02 2.07±0.45
All the values are mean+/-standard deviation.
https://doi.org/10.1371/journal.pcbi.1006752.t001
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Fig 3. The top important features by Elastic Net for each cell line. Cell-line independent as well as cancer subtype-
specific features can be identified by evaluating the regression coefficients of the Elastic Net model. Features such as
TOP1MT, TOP2A/B has shown consistently positive coefficients as compared to features such as AKT1/2/3 which showed
cancer subtype specificity in breast cancer (indicated as arrows).
https://doi.org/10.1371/journal.pcbi.1006752.g003
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example, DNA topoisomerases including TOP1MT, TOP2A and TOP2B and TOP1 were
selected, with average coefficients of 8.2, 2.7, 2.6 and 1.0, respectively. Despite the difference in
the level of variable importance, all the DNA topoisomerases showed positive coefficients in 38
of 39 cell lines, suggesting that targeting DNA topoisomerases were associated with a higher
CSS. DNA topoisomerases are known proteins which are essential for cell replication and
metabolism [37]. Including a topoisomerase inhibitor can thus enhance the drug combination
sensitivity in many cancer cell lines. On the other hand, the only cell line that showed negative
coefficients for TOP1MT was LNCAP (prostate cancer), which turned out to be the cell line
that has the smallest average CSS scores for drug combinations involving the TOP1MT inhibi-
tor (topotecan) (S7 Fig).
If the CSS profiles for two cell lines are similar, then their feature importance vectors are
expected to be similar. We focused on the most important features that have their absolute
coefficients greater than 3 for at least one cell line, resulting in 67 top features. We then utilized
these feature importance scores to cluster the cancer cell lines, using unsupervised hierarchical
clustering with the Euclidean metric. We found that cell lines of the same tissue type did not
necessarily cluster together, indicating their distinctive drug combination response profiles.
For example, we found that breast cancer cell lines did not form a single cluster due to the out-
lier MDAMB436. Indeed, MDAMB436 is the only triple negative breast cancer (TNBC) sub-
type, while the other cell lines are either ER positive (KPL1, ZR751 and T47D), or HER2
positive (EFM192B and OCUBM). It has been known that TNBC respond to anticancer drugs
differently from ER and HER2 positive breast cancers due to distinct disease mechanisms [38].
The top drug combination features separated these two distinctive breast cancer subtypes, sug-
gesting the validity of using CSS-predictive features to cluster cancers of different subtypes.
Furthermore, we found that AKT targets (AKT1/2/3) were among the top features that showed
higher importance in the non-TNBC group. A combination of an AKT inhibitor and a
TOP1MT inhibitor therefore can be proposed to treat non-TNBC, but not necessarily for
TNBC breast cancers. On the other hand, we found that CHEK1 and PARP3/4 targets were
selected for the TNBC cell line MDAMB436 but not for the non-TNBC group, suggesting that
a combination of a CHEK inhibitor and PARP inhibitor might be effective for TNBC. The
mechanisms of actions for the proposed drug combination may prove interesting for experi-
mental validations. Taken together, the pharmaco-features that were determined from the CSS
prediction may help pinpoint the underlying target combinations, which are of pivotal impor-
tance to explain the drug combination responses.
The S synergy scores can predict the true synergy and antagonism
Next, we defined the degree of drug synergy as the differences between the dose-response
curves of a drug combination and its single drugs. We derived three variants of the S synergy
score (Ssum, Smax, Smean) and compared them with the HSA, Bliss, Loewe and ZIP synergy
scores that were determined using the full-dose response matrix. Although being determined
using only one row and one column from the dose-response matrix, all the S synergy scores
Table 3. Pearson correlations of the S synergy scores with those derived using four reference models that were cal-
culated using the full dose-response matrices.
Synergy Scores HSA Bliss Loewe ZIP
Ssum 0.72 0.72 0.46 0.55
Smax 0.71 0.65 0.51 0.49
Smean 0.65 0.63 0.41 0.44
https://doi.org/10.1371/journal.pcbi.1006752.t003
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managed to obtain a good correlation with the synergy scores based on the full matrix design
(Table 3).
We found that the S synergy scores correlated relatively well with the HSA and Bliss scores,
while the correlation started to decrease when comparing to the Loewe and ZIP scores. Since
all the synergy scoring models utilized different assumptions for the reference of no synergy,
we therefore did not expect a perfect correlation in such pairwise comparisons. For example,
the Bliss model assumes that two non-interactive drugs act independently while the Loewe
model assumes two non-interactive drugs act as one drug. Their differences in mathematical
models have been discussed in our previous publications, such as [16] and [35].
Of all the three variations of S synergy score, we found that Ssum showed the best correlation
with those determined using the full dose-response matrix. As Ssum considers the additive
effect of single drug sensitivities as the expectation of no synergy, it thus can be considered a
more conservative scoring method compared to Smax and Smean, where the maximal and aver-
age effect of single drugs were considered as reference separately. To control the false discovery
rate of detecting synergistic combinations, we therefore proposed Ssum as a more appropriate
scoring method for the cross drug combination design.
Next, we evaluated the predicting accuracy of the S synergy scores for true synergistic and
antagonistic drug combinations. To be able to formulate a binary classification problem, we
first selected the true positive and true negative drug pairs by applying stringent criteria to
determine the ground truth from the full dose response matrix data. The rationale of the
ground truth was based on the assumption that full dose-response matrix can capture the truly
synergistic and truly antagonistic drug combinations, as it allows the full factorial testing of all
the possible doses for a given drug combination. However, as there exist different models for
synergy scoring, we decided to apply the most stringent criteria to determine the ground truth,
such that a truly synergistic or truly antagonistic drug combination has to fulfill the criteria of
all the four existing synergy scoring models (HSA, Bliss, Loewe and ZIP). Namely, the drug
combinations with all the four synergy scores (HSA, Bliss, Loewe and ZIP) higher than 5, or
lower than -5, were classified as true synergistic or antagonistic drug combinations, respec-
tively. The threshold of [–5, 5] was determined by the empirical distribution of the synergy
Fig 4. Identification of true synergistic and true antagonistic drug combinations. (A) The ROC curves for the S synergy scores to
detect true synergistic and antagonistic drug combinations. (B) The S-S plot for all the drug combinations. The drug combinations
with the 75th percentile and above for both the CSS and the S scores were highlighted in red to be considered as the prioritized hits
for further experimental validation in a confirmatory screen using a full dose-response matrix design.
https://doi.org/10.1371/journal.pcbi.1006752.g004
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scores in the O’Neil data, assuming that most of the drug combinations are non-interactive (S8
Fig). Furthermore, we considered that a synergy score of [–5, 5] range corresponds to a [–5, 5]
% inhibition which might be due to experimental variation, as indicated by the analysis of rep-
licates from O’Neil dose-response matrix data (mean standard deviation of % inhibition is
6.6%). Therefore, any synergy score between [–5, 5] may be simply experimental noises. From
the O’Neil data, we showed that 78.1% of the drug combinations were within the [–5, 5] range
by at least one synergy scoring, suggesting that the majority of the drug combinations indeed
should not be reliably considered as true synergistic nor true antagonistic (S8 Fig). As a result,
we identified 3,716 true synergistic and 218 true antagonistic drug combinations. All the other
drug pairs were considered as non-interactive and thus excluded from the analysis.
Once the ground truth had been determined using the full dose-response matrix data, we
then asked the question: Can the S synergy scores that were determined using the cross design
correctly identify the most significant synergistic and antagonistic drug combination hits that
were confirmed using the full matrix design? We showed that the S synergy scores achieved
the area under the ROC curves of 0.997 (Ssum), 0.996 (Smax) and 0.992 (Smean) to detect the true
synergistic and antagonistic combinations (Fig 4A). The area under the precision-recall curves
were 0.9997 (Ssum), 0.9995 (Smean) and 0.9998 (Ssum), suggesting that the S scores retrieved a
majority of synergistic combinations with minimal false positive and false negative rates (S9
Fig). The S synergy score was derived from the cross design, where only two vectors of the
drug combination responses are needed. Still, the S synergy scores can predict the most syner-
gistic and antagonistic drug combinations with high accuracy. These results showed that the
cross design can be reliably utilized as a cost-effective strategy in a primary screen to detect the
most significant synergistic or antagonistic drug combinations. On the other hand, the S syn-
ergy score and the CSS drug combination sensitivity score utilize the same unit as the percent-
age of inhibition of cell viability. Therefore, the synergy score can be interpreted as the extra
percentage inhibition effect beyond the expectation. We summarized both CSS and S scores
for all the drug combinations as an S (sensitivity)-S (synergy) plot (Fig 4B; S4 Table). By apply-
ing a threshold of the 3rd quantiles for CSS and S, we can clearly identify the most promising
drug combinations that fulfill both the sensitivity and synergy criteria, while avoiding the false
positive drug combinations that might be synergistic but do not achieve a sufficient high level
of sensitivity (S10 Fig). Taken together, the combined use of CSS drug combination sensitivity
score and the S synergy score allows a simultaneous evaluation of the sensitivity and synergy
for a drug combination, which will facilitate a more systematic analysis of high-throughput
drug combination data with much less experimental materials.
Discussion
Drug combinations may potentially lead to more durable clinical responses by overcoming
intra-tumoral heterogeneity and drug resistance to monotherapies. Identifying drug combina-
tions that are tailored for personalized medicine is a challenge, as the number of possible com-
binations may easily grow exponentially [39]. High-throughput drug combination screening
has been increasingly utilized for early detection of true synergistic and effective drug combi-
nations. However, systematic identification of drug combinations is difficult, as the concepts
of synergistic versus effective drug combinations are often intertwined and sometimes inter-
changed without sufficient clarification. Furthermore, there is a lack of consensus on what the
definition of synergy and sensitivity are, which might contribute to the poor reproducibility of
many drug combination studies. The uncertainty about the endpoint measurement in drug
combination screens brings additional complexity for any machine learning approach to tackle
the prediction problem.
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We developed a novel scoring approach called CSS for drug combinations that can be effi-
ciently determined using the cross design. We found that the CSS is highly reproducible and
therefore can be considered as a robust metric to characterize drug combination sensitivity.
To understand the drug combination sensitivity, we implemented a systematic evaluation of
the prediction accuracy of three machine learning methods. We showed that machine learning
in general worked well for the prediction of CSS, where Elastic Net showed the best perfor-
mance according to our cross-validation setting. We found that the drug target information
for the compounds as well as their chemical fingerprints are highly predictive of the CSS val-
ues, with an accuracy comparable to the level of experimental replicates. Therefore, the ratio-
nale of considering a drug combination as a function of their target and fingerprint profiles
can be justified. This would also allow the augmentation of single-drug screening and drug
combination screening data together to train a machine learning model, as many drugs are
multi-targeted which are equivalent to a drug combination with the same target profile. In our
study, we utilized the SEA method to predict new targets of compounds, by applying a combi-
nation of thresholds of Z-score, Tanimoto coefficient and p-value suggested by the authors of
SEA [25]. In addition to the predicted targets, we also included the known primary and sec-
ondary targets of the compounds, so that the risk of false negative is minimal. However, we
could not find significant improvement on the prediction accuracy when including the SEA-
predicted secondary targets (Table 2), suggesting that the unknown targets for a compound
may contribute minimally to the drug combination sensitivity. In this study we focused on
drug combination prediction within the same cell line. In the future, we could include the
molecular features of the cell lines to improve the prediction accuracy, aiming to identify drug
combination specific biomarkers across different cell lines. On the other hand, as the focus of
the study is to propose the new experimental design and to justify its associated drug combina-
tion scoring methods, we tested the predictability of CSS using only conventional machine
learning methods with standard cross-validation schemes. A more comprehensive evaluation
of machine learning approaches may be developed by including multiple cross-validation
schemes and data pre-filtering techniques. More advanced machine learning methods such as
Deep Learning [13] or network-based methods [40] may further improve the prediction accu-
racy as well as help the biological understanding of the mechanisms of action.
A truly promising drug combinations shall reach sufficient therapeutic efficacy via a strong
sensitivity and synergy. Therefore, both these aspects should be evaluated for the prioritization
of most potential drug combination hits. While there have been multiple synergy scoring
methods that can be applied to the full matrix design, they do not always produce consistent
results. The truly synergistic and antagonistic drug combinations may therefore be determined
by achieving the consensus across the different scoring methods [16]. Based on the CSS drug
combination sensitivity scoring, we developed an S synergy score to quantify the degree of
interactions in a drug pair, and showed that it can identify truly synergistic and antagonistic
drug combinations accurately. Tailored for the cross design, the S synergy score can be used
for the prioritization of a primary drug combination screen, after which only the most signifi-
cant drug combinations should warrant a confirmation screen using the full matrix design.
Furthermore, we proposed a novel S-S plot (Fig 4B) to visualize drug combination sensitivity
and synergy using the same scale, which enables an unbiased way to explore high-throughput
drug combination data more efficiently with minimal bias. Notably, the CSS is defined at the
IC50 concentrations of the background drugs. Therefore, a synergistic drug combination deter-
mined by the S score should be more therapeutically relevant than a drug combination where
the synergy is detected at higher concentrations, which are often associated with unwanted
off-target effects and side-effects.
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The proposed cross design aimed for alleviating the limitation of the conventional dose-
response full matrix design which usually requires a large amount of cancer cells that may not
be amenable especially from patient-derived samples. Empowering the cross design with the
CSS and S scoring methods, we are foreseeing a lower technical barrier to carry out large-scale
drug combination studies with minimal cellular materials. Although we showed the proof-of-
concept using the drug combination data involving cancer cell lines, the cross design coupled
with the CSS and S scoring methods can be readily applied for ex_vivo drug screening, where
the amount of patient-derived materials can be extremely limited and technically difficult to
obtain due to culture constraints [41]. While the majority of drug combination screens are
limited to cytotoxic and molecularly targeted molecules, the cross design should be also
favored for the testing of combinations that involve immunotherapies and antibodies. Further-
more, the cross design is not only applicable for cancer but also for other diseases, as long as
cellular phenotypes of interests can be measured at multiple dose levels. With the help of cross
design and its data analysis tools, drug combination discovery can be more quickly advanced
and may eventually lead to the validation of personalized drug combinations in clinical trials.
Supporting information
S1 Table. Drug target profiles including experimentally-validated primary and secondary
targets, and SEA-predicted secondary targets for the 38 compounds.
(XLSX)
S2 Table. The chemical information including MACCS fingerprint profiles for the 38 com-
pounds.
(XLSX)
S3 Table. The Pearson correlations of the CSS values obtained using the average of four
viability replicates, with the CSS values obtained from the replicate separately.
(XLSX)
S4 Table. CSS drug combination sensitivity scores and S synergy scores for each drug com-
bination.
(XLSX)
S1 Fig. The relation between original AUC and normalized AUC0. AUC is defined as the
area under the log10 transformed drug combination dose response curve on the foreground
drug concentration interval [c1, c2], while AUC0 normalizes AUC by subtracting the area of the
rectangular box with the height of minimal inhibition (%min) considered to be experimental
noise, and then scaled by the factor of (1 − %min)(c2 − c1).
(TIF)
S2 Fig. The heatmap of the CSS1-CSS2 correlations sorted by drug combinations. Drug
classes are determined by their primary targets.
(TIF)
S3 Fig. The scatter plot of the CSS1 and CSS2 values obtained using permuted data. The
color of the data points represents the tissue of origin.
(TIF)
S4 Fig. Reproducibility of CSS values over the replicates. The line plot of the minimal and
maximal values for the CSS replicates combined with CSS values over the standard deviation
of the CSS replicates.
(TIF)
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S5 Fig. The coefficient of variation (CV) for each drug in the single drug screens. The Pear-
son correlations between CSS1 and CSS2 for the drug combinations that involve a given drug
were shown on top of each bar.
(TIF)
S6 Fig. The Pearson correlation between CSS1 and CSS2 after filtering out the drug combi-
nations that have absolute difference between CSS1 and CSS2 over than a given threshold.
The threshold of 10 achieved a correlation (0.93) close to the midpoint (0.91) of the range.
(TIF)
S7 Fig. The Pearson correlation between the variable importance of TOP1MT and the
average CSS for TOP1MT inhibitor for all the 39 cell lines. LNCAP is the only line which
has a negative variable importance for TOP1MT.
(TIF)
S8 Fig. The distribution of (A) minimal and (B) maximal of Loewe, Bliss, HSA and ZIP
synergy scores derived from the dose-response matrix data. True synergistic combinations
were determined as the minimal of the four scores higher than 5 while true negative combina-
tions have the maximal of the four scores lower than 5, resulting in 20.7% and 1.2% of the total
drug combinations respectively.
(TIF)
S9 Fig. The precision-recall curves for the S synergy scores to predict true synergistic (posi-
tive) and true antagonistic (negative) drug combinations, demonstrating that the high
true positive rate is not a consequence of imbalanced classes.
(TIF)
S10 Fig. Examples of the synergistic but not sensitive drug combinations. All the drug com-
binations shown here have an S synergy score higher than 5, while their CSS score lower than 10.
The cell lines are colored based on their tissues of origin. Bar plot in the inset shows the mean %
inhibition that can be achieved by these drug combinations (denoted as false positive group), as
compared to the top 100 drug combinations ranked by CSS (denoted as true positive group).
(TIF)
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